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ABSTRACT
Introduction: Detecting upper gastrointestinal
(GI) cancers in primary care is challenging, as
cancer symptoms are common, often non-
specific, and most patients presenting with
these symptoms will not have cancer. Substan-
tial investment has been made to develop
biomarkers for cancer detection, but few have
reached routine clinical practice. We aimed to
identify novel biomarkers for upper GI cancers
which have been sufficiently validated to be
ready for evaluation in low-prevalence
populations.
Methods: We systematically searched MED-
LINE, Embase, Emcare, and Web of Science for
studies published in English from January 2000
to October 2019 (PROSPERO registration
CRD42020165005). Reference lists of included
studies were assessed. Studies had to report on
second measures of diagnostic performance
(beyond discovery phase) for biomarkers (single
or in panels) used to detect pancreatic, oeso-
phageal, gastric, and biliary tract cancers. We
included all designs and excluded studies with
less than 50 cases/controls. Data were extracted
on types of biomarkers, populations and out-
comes. Heterogeneity prevented pooling of
outcomes.
Results: We identified 149 eligible studies,
involving 22,264 cancer cases and 49,474 con-
trols. A total of 431 biomarkers were identified
(183 microRNAs and other RNAs, 79 autoanti-
bodies and other immunological markers, 119
other proteins, 36 metabolic markers, 6 circu-
lating tumour DNA and 8 other). Over half
(n = 231) were reported in pancreatic cancer
studies. Only 35 biomarkers had been investi-
gated in at least two studies, with reported
outcomes for that individual marker for the
same tumour type. Apolipoproteins (apoAII-AT
and apoAII-ATQ), and pepsinogens (PGI and
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PGII) were the most promising biomarkers for
pancreatic and gastric cancer, respectively.
Conclusion: Most novel biomarkers for the
early detection of upper GI cancers are still at an
early stage of matureness. Further evidence is
needed on biomarker performance in low-
prevalence populations, in addition to imple-
mentation and health economic studies, before
extensive adoption into clinical practice can be
recommended.
Keywords: Biomarkers; Clinical practice; Early
detection; Primary care; Upper gastrointestinal
cancers
Key Summary Points
We aimed to identify novel biomarkers
which had been validated and showed
sufficient promise to warrant further
evaluation in low-prevalence populations.
We identified 431 unique biomarkers;
only 35 of which had been investigated in
at least two studies, with outcomes for
that individual marker for the same
tumour type - four of these were identified
as the most promising for future studies.
This review highlights the need for more
biomarker studies that consider primary
care/community settings as their intended
populations.
Findings also indicate we still need better
reporting to facilitate knowledge
translation; we also need more
consistency in the use of biomarkers.
Research collaborations are vital to reduce
duplicate efforts and ensure appropriate
samples sizes when studying low-
prevalence populations.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13214843.
INTRODUCTION
Gastrointestinal (GI) cancers represented more
than 25% (4.8 million) of cancer cases and over
a third (3.4 million) of cancer-related deaths
worldwide in 2018 [1]. Upper GI cancers con-
tribute an important proportion of these, with
over 2.1 million new cases of cancers of the
stomach, oesophagus, pancreas and biliary tract
diagnosed worldwide in 2018 [1, 2]. Prognosis is
often poor as upper GI cancers are generally not
detected until the disease is advanced and less
amenable to curative treatment [1].
Primary care plays a key role in the early
detection of upper GI cancers, as more than
90% of patients present with symptoms [3–5],
and screening tests for asymptomatic popula-
tions are not yet widely established. Early
detection of upper GI cancers is challenging, as
initial symptoms such as indigestion, abdomi-
nal discomfort or fatigue are common, often
intermittent, and most patients presenting with
them will not have cancer [6, 7].
There is growing demand to improve early
cancer detection through better diagnostic and
triage approaches, particularly for use in pri-
mary care or other community settings where
cancer prevalence is low [5]. New diagnostic
approaches, applied either among asymp-
tomatic at-risk populations or to triage patients
presenting with cancer symptoms, could be
transformational. Electronic health records and
large population-based surveys have been used
to develop cancer risk prediction models to
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identify those requiring investigation for cancer
[8]; diagnostic pathways have also been imple-
mented in different countries in an effort to
improve timely cancer diagnosis [5]. Innovative
strategies applying artificial intelligence tech-
niques to imaging and other medical data are
also promising [5, 9]. For cancers with non-
specific symptom signatures, like most upper GI
cancers, we also need better biomarkers to sup-
port diagnostic assessment [10]. Biomarkers
such as carcinoembryonic antigen (CEA) and
CA19-9 are used in clinical practice predomi-
nantly for surveillance following treatment of
upper GI cancers [9, 11]. Substantial investment
has been made into developing new biomarkers
for early cancer detection; most such biomarker
research has been conducted in laboratory and
specialist clinical settings [12, 13], where cancer
prevalence is higher compared to community
settings [14, 15].
The distinction between care settings is
important, as the diagnostic performance char-
acteristics of a test are strongly determined by
the prevalence and severity of the target disease
and of other diseases within the study popula-
tion [14]. In populations in which the preva-
lence of the target disease is low (e.g. primary
care), positive predictive values are lower than
in high-prevalence populations seen in special-
ist cancer centres. Tests evaluated in high-
prevalence populations tend to have lower
sensitivity and higher specificity when used in
low-prevalence populations [15, 16]. This is
known as the spectrum effect or spectrum bias
[14, 15] and has crucial implications for trans-
lating results from one care setting to another.
To gain an accurate understanding of how a test
will perform within a low incidence setting, it
must ultimately be evaluated within that
setting.
In recognition of this, the CanTest Frame-
work has been developed, proposing a 5-phase
translational pathway for diagnostic tests, from
new test development to health system imple-
mentation in low-prevalence populations [15].
The framework highlights the importance of
evaluating not only clinical performance but
also the feasibility and acceptability of imple-
mentation, patient safety and quality of care,
and cost-effectiveness in the chosen clinical
setting. Understanding and addressing these
issues is vital, as test performance alone, even if
evaluated in the target populations, does not
guarantee clinical utility nor improved patient
outcomes [12].
This review set out to systematically identify
novel biomarkers for the early detection of
upper GI cancers which have been validated
and show sufficient promise to warrant further
evaluation in low-prevalence populations.
METHODS
Search Strategy and Inclusion/Exclusion
Criteria
This systematic review followed the Preferred
Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) guidelines [17], and the
protocol was registered in PROSPERO
(CRD42020165005). We searched MEDLINE,
Embase, Emcare and Web of Science from 1
January 2000 to 31 October 2019 for primary
studies published in English. The search strat-
egy (Online supplementary file 1) was devel-
oped with the assistance of a medical librarian
and refined until it identified all relevant core
publications known by the senior authors. Ref-
erence lists of included studies were also
screened. Articles that were not available online
were ordered via the British Library.
Studies were included if they reported on at
least one measure of diagnostic performance:
sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), false
positive, false negative or area under the curve
(AUC) for biomarkers used to detect oesopha-
geal, gastric, pancreatic or biliary tract cancers.
We included adult populations (mean/median
age C 18); we accepted individuals aged\ 18 if
these were outliers in large samples. The search
strategy also included terms for lower GI (col-
orectal and anal) cancers for the purposes of a
parallel review of novel biomarkers for the early
detection of lower GI cancers, to be reported
separately. Non-specified GI cancers, neuroen-
docrine cancers and studies only reporting on
familial populations at risk of hereditary cancers
were excluded.
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Novel biomarkers were considered both
individually and as part of a combination/panel
test. Studies reporting only the performance of a
single, established biomarker (i.e. CEA and
CA19-9 for pancreatic cancer) were not eligible
for inclusion [9]. We included studies reporting
on performance for established biomarkers if
these were in combination with additional
novel biomarkers.
We aimed to identify studies situated within
Phase 2 (measures of diagnostic accuracy in
high-prevalence settings) and Phase 3 of the
CanTest framework (measures of diagnostic
accuracy or clinical utility, acceptability and
feasibility in intended low-prevalence settings)
(Fig. 1) [15]. We included studies if they repor-
ted more than preliminary measures of perfor-
mance calculated in a discovery phase; this
required additional measures of diagnostic per-
formance in an independent cohort. If no ref-
erences to previous studies evaluating perfor-
mance were available and the study provided
only one set of measures, the study was exclu-
ded. Panels with previously investigated
biomarkers were included even if the biomark-
ers had not been investigated as part of a panel.
As larger sample sizes are required beyond the
biomarker discovery phase [13, 18], studies had
to include at least 50 cancer cases and at least
one group of 50 non-cancer controls with sim-
ilar clinical characteristics (healthy, or with
non-malignant or pre-malignant conditions).
Similar criterion has been adopted by previous
reviews that informed our study [13, 19].
We only included biomarkers which are
feasible to use in a community setting, i.e.
blood (serum and plasma), urine, faecal, salivary
or breath samples. Observational studies (cross-
sectional or longitudinal, prospective or retro-
spective) and trials were eligible for inclusion.
Fig. 1 The CanTest Framework Reproduced with permission from [15]
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We included all recruitment settings, as we
expected that very few studies would have been
carried out in community settings.
We used the online tool Covidence [20] to
facilitate title and abstract screening and study
selection. Two reviewers (any two of NC, PED,
CS, KMM, DB or RB) independently screened
titles and abstracts. Then, two reviewers (any
two of the above) independently evaluated full-
text articles for inclusion. Titles and abstracts of
reference lists of included studies were reviewed
by one author (NC); full-text articles selected at
this stage were independently assessed by two
reviewers (any two of NC, PED, RB or DB). Dis-
agreements were resolved by consensus; when
this could not be reached a senior, third
reviewer (FMW or JE) was consulted.
Data Extraction and Analysis
Data extraction was piloted to ensure consis-
tency and was carried out by one of seven
reviewers (NC, PED, RB, DB, JMG, JO and SS).
We extracted information on: study character-
istics (publication year, country of population
of interest, recruitment setting, study aims and
design); populations (numbers included, age,
sex, tumour staging for cases and health status
for controls); biomarkers (type of sample, bio-
marker name, biomarker category); and sum-
mary measures of diagnostic performance
(sensitivity, specificity, PPV, NPV, false posi-
tives, false negatives and AUC, with 95% con-
fidence intervals when available, for all
comparisons). When studies reported on dif-
ferent phases of biomarker development, we
only extracted data from the eligible phases (i.e.
biomarkers and measures beyond the discovery
phase). When studies had more than one eligi-
ble phase, we extracted data from all phases.
Extracted data were collated and checked for
consistency and inaccuracies (NC).
Biomarkers were categorised according to a
modified version of Uttley et al.’s classification
[19], which included: microRNAs and other
RNAs, autoantibodies and other immunological
markers, other proteins (that did not fit into
other categories), metabolic markers, circulat-
ing tumour DNA, and other biomarkers. Con-
trols were classified as: normal/healthy, having
non-malignant, or pre-malignant conditions.
Biomarkers and control populations were coded
by one author (NC) and checked by other
authors (PED, KMM and MM; and PED, FMW
and JE, respectively). Controls described as
being healthy were coded as such unless studies
described underlying conditions. Patients with
cancer were ineligible as controls. Full details of
the classification of controls are available (on-
line supplementary table S1). Microsoft Excel
2015 and SPSS v.23 (IBM) were used for data
extraction and data analysis.
Quality Assessment and Risk of Bias
Risk of bias [21] was not assessed as described in
the original protocol, following independent
piloting. Appraisal was hindered by the use of
diverse methods across studies and incomplete
reporting, resulting in a large number of ‘‘un-
clear’’ assessments. Instead, a list of issues
identified in the studies was prepared (Online
supplementary file 2). As spectrum bias is a key
issue when translating results from high- to low-
prevalence populations, all included studies
were classified as either single-gate or two-gate
designs. In single-gate designs, cases and con-
trols are recruited through a single route of
entry and with the same inclusion criteria (e.g.
all cases and controls presented with symp-
toms). In two-gate designs, participants are
recruited through different routes and different
inclusion criteria exist for cases and controls. In
this situation, controls can be either normal/
healthy or with an alternative diagnosis, which
can produce symptoms and signs similar to
patients with cancer [16]. One author (NC)
classified all studies and another (PED) checked
the classification. A full description of this
classification and how it approaches some of
the issues covered by the critical appraisal tool is
available (Online supplementary file 3).
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Data Synthesis
Included studies were heterogeneous and rarely
evaluated the same biomarkers in the same way,
often using different cut-off points, populations
and/or biomarker combinations in panels.
Therefore, we were unable to undertake meta-
analysis. Instead, we used narrative synthesis to
summarise data across studies [22]. First, we
developed an overview of the available evi-
dence, describing key characteristics of included
studies, their populations and biomarkers, and
outcome measures. Then, we looked for simi-
larities that would allow for subgroup analyses,
namely the same biomarker, for the same
tumour type, with similar designs, outcome
measures and populations.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Database searches identified 16,597 records;
9172 were retained after removing duplicates.
During title and abstract screening, 8179 ineli-
gible records were excluded. The full texts of the
remaining 993 records were assessed for eligi-
bility; 731 were excluded (Fig. 2). A total of 262
studies from database searches met inclusion
criteria; 25 additional studies were identified in
reference lists. Of these, 149 included studies
referred to upper GI cancers and were included
in our narrative synthesis.
Characteristics of Included Studies
Key characteristics of included studies are
described in Table 1 and 2. Most studies recrui-
ted participants from a single country (n = 142).
China was the most common country (n = 77),
followed by Japan and South Korea (n = 15
each), the USA (n = 12) and Germany (n = 9).
The most common recruitment settings were
hospital or other secondary care institutions
(n = 125), biobanks, reference sets, databases or
archived samples (n = 20), general population
cohorts or cohorts from population screening
programmes (n = 11) and cohorts from previous
trials or observational studies (n = 9). Several
studies recruited from more than one setting.
Gastric cancer was the most commonly inves-
tigated tumour type (n = 69), followed by pan-
creatic (n = 54), oesophageal (n = 24) and
biliary tract cancers (n = 3). Four studies inves-
tigated more than one type of upper GI cancer
(Table 1).
Characteristics of Cases and Controls
Overall, the included studies reported on 22,264
cancer cases (10,589 gastric, 7964 pancreatic,
3258 oesophageal and 290 biliary tract cancers,
and 163 oesophago-gastric cancers, not


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































distinguishing between oesophageal and gastric
cancer). The minimum age for cases was 16
while the oldest patient was aged 93. Most cases
were male (68%) across all tumour types. Over
50% of cancers had been diagnosed at stages III
and IV (median 55.5%, interquartile range
47.0–68.1%; data available for 106 included
studies). The included studies reported on
49,474 controls (38,955 normal/healthy, 9042
with non-malignant conditions, 1106 with pre-
malignant conditions, and 371 with either
normal or non-malignant conditions). Pancre-
atitis and gastritis were the most commonly
reported non-malignant conditions (online
supplementary Figure S1). Over half of the
studies (n = 83) investigated more than one
type of control population. Normal healthy
controls were the majority across all tumour
types, except for biliary tract cancers. The min-
imum age for controls was 16 while the maxi-
mum age was 94. Overall, most controls were
male (74%); this was the case for all tumour
types except for biliary tract cancers.
Types of Biomarkers
Biomarkers were most commonly sampled from
blood (145 studies; 107 investigated serum, 33
plasma and 5 both); two studies analysed urine
[28, 36], one breath [169] and another saliva
[47]. Most studies (n = 128) investigated more
than one biomarker. A total of 431 biomarkers
were identified (online supplementary table S2).
These were most often microRNA and other
RNAs (n = 183), other proteins (n = 119) and
autoantibodies and other immunological
markers (n = 79). Less than a third of studies
(n = 44) included biomarkers from different
categories. This was often due to use of estab-
lished biomarkers (proteins CA19-9 and CEA) in
combination with novel biomarkers. Studies of
pancreatic cancer reported on over half of
identified biomarkers (n = 231) (Fig. 3). Only
about a fifth (n = 90) of all identified biomarkers
were reported in more than one study; 72 of
these were reported in more than one study for
the same tumour type (Table 3).
Measures of Diagnostic Performance
The most commonly reported measures of
diagnostic performance were sensitivity
(n = 136), specificity (n = 129) and AUC
(n = 123). PPV and NPV were each reported by
40 studies, while false positives and false nega-
tives were least often reported (11 studies each).
Outcome data on individual biomarkers were
available in most studies (n = 121); the
remaining 28 studies only reported on perfor-
mance for a combination/panel. Over half of
the included studies (n = 83) reported on mea-
sures of performance for biomarkers both indi-
vidually and in combinations. Outcome data
were not available for all control populations;
only 95 studies provided outcome data for
cancers versus normal controls, 54 provided
outcome data for cancers versus non-malignant
controls, and 10 provided measures for cancers
Fig. 3 Types of biomarkers, overall and by tumour type.
aFive proteins; bthese refer to volatile organic compounds
and platelets; autoab autoantibodies, ctDNA circulating































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































versus pre-malignant conditions (online sup-
plementary table S3).
Individual measures of diagnostic perfor-
mance were available for 35 biomarkers men-
tioned more than once, for the same tumour
type (online supplementary table S4). We were
not able to synthesise outcomes further due to
heterogeneity in biomarker combinations, in
control populations and subgroup analyses, and
variations in reported cut-off points and diag-
nostic accuracy data (see online supplementary
table S5 for a textual description of outcomes).
Only four novel biomarkers were reported on
studies adopting a single-gate design (Table 4).
Apolipoproteins AII-AT and AII-ATQ had poor
sensitivity (range 4–25%) but good AUCs (range
52–94.6%) reported for pancreatic cancer in
three studies (same first author for all)
[104–106]. Their diagnostic accuracy increased
when combined with CA19-9 (sensitivity range
7–95.4%, specificity range 96–98%, AUC range
56–78%). Pepsinogen I (PGI) and PGI/PGII ratio
had a wide range of sensitivity and specificity
(ranges 27–77.9% and 20.2–92%, respectively)
and good AUC (range 70–76%) reported for
gastric cancer across four studies [29, 40, 41, 76].
When evaluated with other novel biomarkers
(including miR-1290, MIC-1, ULBP2 and
CA125), one established biomarker, CA19-9,
also showed some promise (sensitivity range
23.1–88%, specificity range 71.6–96.6%, AUC
92–98%) for pancreatic cancer [121, 132, 138].
There were also two studies reporting panels
rather than individual biomarkers using a sin-
gle-gate, reversed-flow design (Table 4)
[89, 119].
DISCUSSION
Our systematic review identified 149 studies
reporting on 431 different biomarkers for gas-
tric, pancreatic, oesophageal and biliary tract
cancers. Only a fifth of biomarkers were repor-
ted by more than one study, and from these
only four novel biomarkers, apoAII-AT and
apoAII-ATQ (pancreatic cancer) and pepsinogen
I and II (gastric cancer), plus one established
biomarker (CA19-9 combined with other novel
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 4 Biomarkers reported more than once for the same tumour type and panels adopting a single-gate (reversed-flow)
design
References Recruitment setting Cases Controls Outcomes (Sensitivity,
specificity, AUC where
available)
1. Measures of diagnostic performance available for individual biomarkers, in studies adopting a single-gate design
















Median age 58.0 (34.5–75.4)
53% male (matched to cases)
Measures for months prior to


























Mean age 62.5 (10.8)
52% male
Measures for ELISA and mass
spectrometric analysis, also
according to tumour staging




CA19-9, 1 cut-off point each
Sensitivity, 95.4% (cohort 2)





Age and sex NA
Staging: majority
advanced stages
57 pancreatic disease other
than IDACP





Age and sex NA
Staging: all early
stages
62 CP, 31 acute benign
biliary obstruction, 61 HC
Age and sex NA
Adv Ther
Table 4 continued
















Does not meet criteria as used
to calculate first measures of
performance
Measures provided according to
tumour staging
For ApoAII-AT/ATQ alone, 1
cut-off point
AUC, 0.953 (cohort 3)
For ApoAII-AT/ATQ plus
CIII-0, and CA19-9, 1 cut-off
point (cohort 4)
Sensitivity, range 91.60–94.20%








Does not meet criteria as









53 HC and 58 CP
HC mean age 39.1 (15.6), CP
50.3 (8.9)














128 HC, 38 benign
tumour/cyst and 14 CP
HC mean 46.6 (16.8), benign
tumour/cyst 63.5 (11.0), CP
60.2 (10.2)
HC 65% male, benign
tumour/cyst 45% male, CP
86% male





50 GC (54% w/
H. pylori)
No information
on age and sex
Staging NA
752 non-cancer (302 antrum
limited CG and/or atrophy
and 450 corpus CG and/or
atrophy (77% w/ H. pylori
Mean age: 53.8 (SD 1,
27–78)
31% male

























172 BGU, 119 DU, 107
dysplasia
Age and sex not available for
controls only
Measures according to tumour
type only (intestinal or
diffuse)




















16 GU or DU, 17 superficial
gastritis, 66 CAG, 79 no
abnormality





Negative or positive PG test
For PGI and PGI/II ratio, strict

















Mean age: 49.2 (4.7)
100% male






References Recruitment setting Cases Controls Outcomes (Sensitivity,
specificity, AUC where
available)
2. Measures of diagnostic performance available for established biomarkers combined with novel biomarkers not shown













Age N/A for validation
100% female
Measures according to time to
diagnosis: 0–4 years,
0–2 years; 1–4 years
For CA19-9 (4 cut-off points)

















Median age 62 (55–70)
45% male











Mean age 56 (SD
13.5)
67% male
Staging: 5 IA, 12
IB, 36 IIA, 20
IIB, 40 III, 39 IV
96 HC, 91 CP, 20 pre-
malignancies
Mean age: HC 58 (7.6), CP
58 (15.0), pre-malignancies
60 (11.3)
HC 75% male; CP 57% male;
pre-malignancy 75% male
For CA19-9 plus MIC-1 and
ULBP2, 1 cut-off point
(each)
AUC 0.982 (PaC and CP only)
For CA19-9 plus MIC-1, 1 cut-
off point (each)
AUC 0.932 (PaC and CP only)
For CA19-9 plus ULBP2, 1
cut-off point (each)
AUC 0.953 (PaC and CP only)
Adv Ther
Table 4 continued
References Recruitment setting Cases Controls Outcomes (Sensitivity,
specificity, AUC where
available)
3. Measures of diagnostic performance available for a panel only in studies adopting a single-gate design (all reversed-flow)






98 PaC (52 w/o
diabetes or
pancreatitis)
Age and sex not
available
Staging: 7 IA, 8 IB,
1 II, 40 IIA and
42 IIB
62 CP, 31 acute biliary
obstruction, 61 HC (50
w/o diabetes or
pancreatitis)
Age and sex not available
Measures for PaC vs. HC, PaC
vs. CP, PaC w/o diabetes or
pancreatitis vs. HC w/o
diabetes or pancreatitis, and
according to staging
For CA19-9 plus TFPI and




















Staging: 15 I, 75 II,
15 III and 38 IV
219 HC, 57 CP
HC median age 63.0
(24–86), CP 55.5 (32–81)
HC 53% male, CP 46% male
Measures available for stages
I ? II combined




AUC, 0.963 (PaC vs. HC) and
0.840 (Pac vs. CP)
ACG atrophic chronic gastritis, ApoAII-AT/ATQ apolipoprotein AII-AT/ATQ, apoCIII-0 apolipoprotein CIII-0, BGU
benign gastric ulcer, DU duodenal ulcer, CG chronic gastritis, CP chronic pancreatitis, EPIC European Prospective
Investigation into Cancer and Nutrition, GC gastric cancer, GU gastric ulcer, IDACP invasive ductal adenocarcinoma of
pancreas, MIC macrophage-inhibitory cytokine 1, MPV mean platelet volume, NA not available, NCI-EDRN National
Cancer Institute Early Detection Research Network, PaC pancreatic cancer, PDAC pancreatic ductal adenocarcinoma,
PDW platelet distribution width, PGI/II serum pepsinogen I/II, PPV positive predictive value, TFPI plasma tissue factor
pathway inhibitor, NTC-FN III-C tenascin-C, UKCTOCS UK Collaborative Trial of Ovarian Cancer Screening, ULBP2
UL16 binding protein 2
a Leelawat et al. [166] also adopted a reversed-flow design but was not added as it was the only study investigating CA19-9
for cholangiocarcinoma
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measures of diagnostic performance, adopting a
recommended single-gate design. Heterogene-
ity in methods, populations, biomarkers, out-
comes and comparisons precluded meta-
analysis. Applying novel biomarkers for the
early detection of upper GI cancers is therefore
at an early stage of matureness: few have been
extensively evaluated and evaluations have
almost exclusively focussed on high-prevalence
populations. Further evaluation of the most
promising biomarkers in low-prevalence popu-
lations is needed before extensive adoption into
routine clinical practice can be recommended.
While other reviews have investigated
biomarkers used for early cancer detection
[19, 172], few have considered the evidence in
the context of future application of tests in low-
prevalence populations, the likely target for
clinical application [12, 13]. To our knowledge,
this is the first review to do so for upper GI
cancers. The four novel and one established
biomarkers we highlight in this review were
evaluated in a mix of high- and low-prevalence
populations, including hospital patients, gen-
eral population cohorts, screening populations
(both high and average cancer risk), and
patients presenting with symptoms. We did not
identify any studies reporting outcomes rele-
vant to feasibility, acceptability, benefits and
harms, nor health economics as initially plan-
ned in the review protocol (i.e. phase 3 studies
and beyond in the CanTest framework). The
best performing biomarkers for pancreatic can-
cer, with an AUC between 56% and 94%, were
ApoAII-ATQ/AT alone, CA19-9 plus miR-1290,
MIC-1 and ULPB2, and Mellby et al.’s [119]
29-panel signature. These may be ready for trials
and other phase 3 studies, single or in combi-
nation, in low-prevalence populations. We did
not identify any novel biomarkers with similar
AUCs for gastric, biliary tract or oesophageal
cancers.
A previous review investigating the role of
pepsinogens in early detection of gastric cancers
reported that they had only moderate capacity
to detect gastric cancer [173]. Another review
on early pancreatic cancer detection high-
lighted that no single biomarker has yet trans-
lated to clinical use and suggested the use of
‘robust panels of biomarkers’ [9]. This review
confirms that more research is required before
we have sufficient evidence about biomarkers
for upper GI cancers to warrant their adoption
into clinical practice.
We identified several important method-
ological limitations within the biomarker stud-
ies to date. These include large numbers of
biomarkers analysed in parallel during discov-
ery studies, increasing risk of falsely positive
results; limited sample sizes; evaluation of ‘‘ex-
treme’’ cases; limited external, independent
validation; and selective reporting for valida-
tion (several alternatives analyses and combi-
nations, use of several cut-off points and over-
optimistic interpretation of the data) [12].
Together with use of two-gate rather than rec-
ommended single-gate designs, these could all
lead to over-inflated measures of performance.
Population characteristics were often provided
as supplementary data, with little discussion of
potential selection bias and other sources of
uncertainty. We also excluded relevant studies
when we could not obtain sufficient informa-
tion on an individual tumour type; this was the
case for the CancerSeek tool [174]. Adoption of
reporting guidelines [175] and development of
early cancer detection collaborations [15, 18]
could be useful strategies to address these issues.
This review offers a comprehensive overview
of the available evidence. It benefitted from
having a multidisciplinary team of experts, a
broad search strategy, independent screening,
and classifications checked by senior team
members. Since meta-analysis was not feasible
nor appropriate, we had to use text and tables to
synthesise the evidence. We did not include
studies investigating biomarkers as part of risk
prediction models or risk assessment tools.
These studies have strong potential to be used
in the community and should be investigated in
a separate systematic review. Recent reviews
indicate that only including studies in English
has minimal impact on review conclusions
[176, 177]. We believe this is also the case for
this review, particularly due to the overall lack
of evidence on biomarkers ready to be evaluated
in low-prevalence settings. Although we did not
formally appraise risk of bias, we identified
several quality and methodological issues,
indicating that challenges already highlighted
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in the literature persisted over time [12]. Finally,
due to the large amount of evidence on bio-
marker development and evaluation, we believe
the field could benefit from a ‘‘living systematic
review’’; this refers to high quality, up-to-date
online summaries of evidence which can be
constantly updated as new research becomes
available [178].
The studies we identified focused on mea-
sures of diagnostic performance, which is rea-
sonable given the phase of development for
most of them. The CanTest Framework [15] can
help guide studies aiming to build much needed
evidence on later phases of biomarker develop-
ment, focussing on impact on clinical decision-
making, patient, health system and economic
outcomes.
CONCLUSION
There is a large body of evidence on biomarkers
being developed for the detection of upper GI
cancers, but relatively few have yet to demon-
strate their validity or clinical utility in settings
where cancer prevalence is low. Early detection
of colorectal cancer already benefits from
biomarkers that can be used across different
populations. This is the case for the faecal
immunochemical test (FIT), which is recom-
mended for use in primary care in Spain, Aus-
tralia and the United Kingdom, in addition to
being effective at mass population screening
programmes, using different cut-off points
[179, 180]. It took several decades from FIT
development to generate evidence for its cost-
effectiveness as a screening test for colorectal
cancer. Its role in the assessment of patients in
primary care with lower GI symptoms is still
being evaluated. Biomarkers for upper GI cancer
remain in their infancy but there are a few
which show promise and require further evalu-
ations. Ultimately, they may be able to con-
tribute to improving outcomes for upper GI
cancers through earlier detection.
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176. Jüni P, Holenstein F, Sterne J, et al. Direction and
impact of language bias in meta-analyses of con-
trolled trials: empirical study. Int J Epidemiol.
2002;31(1):115–23.
177. Nussbaumer-Streit B, Klerings I, Dobrescu AI, et al.
Excluding non-english publications from evidence-
syntheses did not change conclusions: a meta-epi-
demiological study. J Clin Epidemiol. 2020;118:
42–54.
178. Elliott JH, Turner T, Clavisi O, et al. Living system-
atic reviews: an emerging opportunity to narrow
the evidence-practice gap. PLoS Med. 2014;11(2):
e1001603.
179. Westwood M, Lang S, Armstrong N, et al. Faecal
immunochemical tests (FIT) can help to rule out
colorectal cancer in patients presenting in primary
care with lower abdominal symptoms: a systematic
review conducted to inform new NICE DG30 diag-
nostic guidance. BMC Med. 2017;15(1):189.
180. van Melle M, Yep Manzano SI, Wilson H, et al.
Faecal immunochemical test to triage patients with
abdominal symptoms for suspected colorectal can-
cer in primary care: review of international use and
guidelines. Fam Pract. 2020 (epub 8 May 2020).
Adv Ther
